Equities

Morepen Laboratories Ltd

MOREPENLAB:NSI

Morepen Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)86.36
  • Today's Change2.76 / 3.30%
  • Shares traded11.94m
  • 1 Year change+135.31%
  • Beta1.4810
Data delayed at least 15 minutes, as of Sep 20 2024 11:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments169217158
Total Receivables, Net3,5612,9782,913
Total Inventory4,6273,9463,925
Prepaid expenses1014527
Other current assets, total432375321
Total current assets8,8907,5627,343
Property, plant & equipment, net2,3771,8401,608
Goodwill, net745745745
Intangibles, net197255307
Long term investments846458
Note receivable - long term637637637
Other long term assets------
Total assets12,93211,10510,701
LIABILITIES
Accounts payable2,9502,2692,581
Accrued expenses288249207
Notes payable/short-term debt235232161
Current portion long-term debt/capital leases211111
Other current liabilities, total5264521,604
Total current liabilities4,0203,2124,565
Total long term debt349.3413
Total debt290252186
Deferred income tax222725
Minority interest0(4.6)(4.61)
Other liabilities, total383333317
Total liabilities4,4603,5764,915
SHAREHOLDERS EQUITY
Common stock1,0221,022956
Additional paid-in capital3,6983,6982,318
Retained earnings (accumulated deficit)3,8392,8772,565
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(86)(68)(53)
Total equity8,4727,5295,786
Total liabilities & shareholders' equity12,93211,10510,701
Total common shares outstanding511511478
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.